Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Stop study of early discontinuation of nivolumab or pembrolizumab in responding advanced melanoma
NL-OMON21032Recruiting
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab and pembrolizumab in melanoma, sponsored by Erasmus MC Cancer Institute. Primary endpoint: Ongoing response rate at 24 months. Started Oct 2018; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON21032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21032.